Basal insulin analogue versus traditional NPH insulin in basal bolus therapy of children and adolescents with type 1 diabetes

Abstract

The efficacy and safety of a combination of ultrashort acting insulin aspart (Novorapid) with determir (Levemir) and glargin (Lantus) versus the traditional NPH-insulin (Protafan) used in basal bolus therapy were evaluated in 112 children and adolescents with type 1 diabetes 12 and 24 weeks after treatment. According to the type of basal insulin, the patients were divided into 3 groups. A significant decrease in HbA_1c levels was revealed in the group of detemir-treated patients. The analogues of basal insulin significantly reduced the risk of hypoglycemias, by simultaneously improving the quality of glycemia control. Their use could cause a significant decrease in the fasting plasma level of glucose, by completely refusing 6.00 extra insulin doses. In the detemir group, the daily dose was increased, by lowering the amount of basal insulin. The dose of dietary insulin underwent changes in the glargin group. Body mass index remained unchanged in the detemir group over 24 weeks of treatment.